Concise Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development

Stem Cells Translational Medicine

Volumn 6, Issue 12, 2017, Pages 2115-2125

  Papaccio, Federica ^a   Paino, Francesca ^a   Regad, Tarik ^a,b   Papaccio, Gianpaolo ^a   Desiderio, Vincenzo ^a   Tirino, Virginia ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

Cancer progression; Drug resistance; Epithelial to mesenchymal transition; Mesenchymal stem cells; Microenvironment

Indexed keywords

GLUTATHIONE TRANSFERASE;

ANGIOGENESIS; CANCER CELL; CANCER STEM CELL; CARCINOGENESIS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; MESENCHYMAL STEM CELL; MESODERMAL CELL; METASTASIS; MULTIDRUG RESISTANCE; NEOPLASM; NONHUMAN; REVIEW; WOUND HEALING; ANIMAL; METABOLISM; PATHOLOGY; TUMOR MICROENVIRONMENT;

ANIMALS; CARCINOGENESIS; HUMANS; MESENCHYMAL STEM CELLS; NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 85032304187     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.1002/sctm.17-0138     Document Type: Review

References (105)

1. Reya T, Morrison SJ, Clarke MF et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105–111.
2. Chamberlain G, Fox J, Ashton B et al. Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007;25:2739–2749.
3. Roufosse CA, Direkze NC, Otto WR et al. Circulating mesenchymal stem cells. Int J Biochem Cell Biol 2004;36:585–597.
4. Lee RH, Kim B, Choi I et al. Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. Cell Physiol Biochem 2004;14:311–324.
5. De Francesco F, Tirino V, Desiderio V et al. Human CD34/CD90 ASCs are capable of growing as sphere clusters, producing high levels of VEGF and forming capillaries. PLoS One 2009;4:e6537.
6. Trubiani O, Di Primio R, Traini T et al. Morphological and cytofluorimetric analysis of adult mesenchymal stem cells expanded ex vivo from periodontal ligament. Int J Immunopathol Pharmacol 2005;18:213–221.
7. Erices A, Conget P, Minguel JJ. Mesenchymal progenitor cells in human umbelical cord blood. Br J Haematol 2000;109:235–242.
8. In't Anker PS, Scherjon SA, Kleijburg-van der Keur C et al. Isolation of mesenchymal stem cells of fetal and maternal origin from human placenta. Stem Cells 2004;22:1338–1345.
9. Ame-Thomas P, Maby-El Hajjami H, Monvoisin C et al. Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumour B-cell growth: Role of stromal cells in follicular lymphoma pathogenesis. Blood 2007;109:693–702.
10. Krampera M, Sartoris S, Cosmi L et al. Immune regulation by mesenchymal stem cells derived from adult spleen and thymus. Stem Cells Dev 2007;16:797–810.
11. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006;119:2204–2213.
12. Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41–49.
13. Smith JR, Pochampally R, Perry A et al. Isolation of a highly clonogenic and multipotential subfraction of adult stem cells from bone marrow stroma. Stem Cells 2004;22:823–831.
14. Sato Y, Araki H, Kato J et al. Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood 2005;106:756–763.
15. Kotton DN, Ma BY, Cardoso WV et al. Bone marrow- derived cells as progenitors of lung alveolar epithelium. Development 2001;128:5181–5188.
16. Horwitz EM, Le Blanc K, Dominici M et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005;7:393–395.
17. Javazon EH, Beggs KJ, Flake AW. Mesenchymal stem cells: Paradoxes of passaging. Exp Hematol 2004;32:414–425.
18. Shiao SL, Ganesan AP, Rugo HS et al. Immune microenvironments in solid tumours: New targets for therapy. Genes Dev 2011;25:2559–2572.
19. Paino F, La Noce M, Di Nucci D et al. Human adipose stem cell differentiation is highly affected by cancer cells both in vitro and in vivo: Implication for autologous fat grafting. Cell Death Dis 2017;8:e2568.
20. Kern S, Eichler H, Stoeve J et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006;24:1294–1301.
21. Izadpanah R, Trygg C, Patel B et al. Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. J Cell Biochem 2006;99:1285–1297.
22. Noel D, Caton D, Roche S et al. Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. Exp Cell Res 2008;314:1575–1584.
23. De Ugarte DA, Morizono K, Elbarbary A et al. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs 2003;174:101–109.
24. Dominici L, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Citotherapy 2006;8:315–317.
25. Ritter A, Friemel A, Fornoff F et al. Characterization of adipose-derived stem cells from subcutaneous and visceral adipose tissues and their function in breast cancer cells. Oncotarget 2015;6:34475–34493.
26. Tirino V, Desiderio V, Paino F et al. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumourigenicity in vivo. FASEB J 2011;25:2022–2030.
27. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646–674.
28. Shmelkov SV, Butler JM, Hooper AT et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumours. J Clin Invest 2008;118:2111–2120.
29. Ren F, Sheng WQ, Du X. CD133: A cancer stem cells marker, is used in colorectal cancers. World J Gastroenterol 2013;19:2603–2611.
30. Brabletz T, Jung A, Spaderna S et al. Opinion: Migrating cancer stem cells—An integrated concept of malignant tumour progression. Nat Rev Cancer 2005;5:744–749.
31. Diaz-Cano SJ. Tumour heterogeneity: Mechanisms and bases for a reliable application of molecular marker design. Int J Mol Sci 2012;13:1951–2011.
32. Zimmerlin L, Donnenberg AD, Rubin PJ et al. Regenerative therapy and cancer: In vitro and in vivo studies of the interaction between adipose-derived stem cells and breast cancer cells from clinical isolates. Tissue Eng Part A 2011;17:93–106.
33. Kozlik M, Wójcicki P. The use of stem cells in plastic and reconstructive surgery. Adv Clin Exp Med 2014;23:1011–1017.
34. Longo UG, Rizzello G, Berton A et al. Potential of adipose derived stem cells in orthopaedic surgery. Curr Stem Cell Res Ther 2013;8:418–421.
35. Gimble MJ, Bunnell BA, Guilak F. Human adipose-derived cells: An update on the transition to clinical translation. Regen Med 2012;7:225–235.
36. Delay E, Garson S, Tousson G et al. Fat injection to the breast: Technique, results, and indications based on 880 procedures over 10 years. Aesthet Surg J 2009;29:360.
37. Illouz YG, Sterodimas A. Autologous fat transplantation to the breast: A personal technique with 25 years of experience. Aesthet Plast Surg 2009;33:706.
38. Yoshimura K, Asano Y, Aoi N et al. Progenitor-enriched adipose tissue transplantation as rescue for breast implant complications. Breast J 2010;16:169.
39. Donnenberg VS, Zimmerlin L, Rubin PJ et al. Regenerative therapy after cancer: What are the risks? Tissue Eng Part B Rev 2010;16:567–575.
40. Perrot P, Rousseau J, Bouffaut AL et al. Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence. PLoS One 2010;5:e10999.
41. Chaput B, Foucras L, Le Guellec S et al. Recurrence of an invasive ductal breast carcinoma 4 months after autologous fat grafting. Plast Reconstr Surg 2013;131:123e–124e.
42. Calorini L, Bianchini F. Environmental control of invasiveness and metastatic dissemination of tumour cells: The role of tumour cell-host cell interactions. Cell Commun Signal 2010;8:24.
43. Kunz-Schughart LA, Knuechel R. Tumour-associated fibroblasts (Part II): Functional impact on tumour tissue. Histol Histopathol 2002;17:623–637.
44. Maffini MV, Soto AM, Calabro JM et al. The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci 2004;117:1495–1502.
45. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today 2000;6:324–329.
46. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013;501:346–354.
47. Yamashita M, Ogawa T, Zhang X et al. Role of stromal myofibroblasts in invasive breast cancer: Stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome. Breast Cancer 2012;19:170–176.
48. Fujita H, Ohuchida K, Mizumoto K et al. α-smooth muscle actin expressing stroma promotes an aggressive tumour biology in pancreatic ductal adenocarcinoma. Pancreas 2010;39:1254–1262.
49. Krampera M, Franchini M, Pizzolo G et al. Mesenchymal stem cells: From biology to clinical use. Blood Transfus 2007;5:120–129.
50. Wu Y, Chen L, Scott PG et al. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 2007;25:2648–2659.
51. Dvorak HF. Tumours: Wound that do not heal. N Engl Med 1986;315:1650–1659.
52. Ridge SM, Sullivan FJ, Glynn SA. Mesenchymal stem cells: Key players in cancer progression. Mol Cancer 2017;16:31.
53. Quante M, Tu SP, Tomita H et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumour growth. Cancer Cell 2011;19:257–272.
54. Tu B, Peng ZX, Fan QM et al. Osteosarcoma cells promote the production of pro-tumour cytokines in mesenchymal stem cells by inhibiting their osteogenic differentiation through the TGF-β/Smad2/3 pathway. Exp Cell Res 2014;320:164–173.
55. Karnoub AE, Dash AB, Vo AP et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;7162:557–556.
56. Muehlberg FL, Song YH, Krohn A et al. Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis 2009;30:589–597.
57. Bonuccelli G, Avnet S, Grisendi G et al. Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumour cells. Oncotarget 2014;5:7575–7588.
58. Fotia C, Massa A, Boriani F et al. Hypoxia enhances proliferation and stemness of human adipose-derived mesenchymal stem cells. Cytothecnology 2015;6:1073–1084.
59. Konala VBR, Mamidi MK, Bhonde R et al. The current landscape of the mesenchymal stromal cell secretome: A new paradigm for cell-free regeneration. Cytotherapy 2016;18:13–24.
60. Chowdhury R, Webber JP, Gurney M et al. Exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget 2015;6:715–731.
61. Waterman RS, Tomchuck SL, Henkle SL et al. A new mesenchymal stem cell (MSC) paradigm: Polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One 2010;5:e10088.
62. Fridman WH, Pagès F, Sautès-Fridman C et al. The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer 2012;12:298–306.
63. Nielsen JS, Sahota RA, Milne K et al. CD20+ tumour-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 2012;18:3281–3292.
64. Mantovani A. MSCs, macrophages, and cancer: A dangerous ménage-à-trois. Cell Stem Cell 2012;11:730–732.
65. Jia XH, Feng GW, Wang ZL et al. Activation of mesenchymal stem cells by macrophages promotes tumour progression through immune suppressive effects. Oncotarget 2016;7:20934–20944.
66. Chanmee T, Ontong P, Konno K et al. Tumour associated macrophages as major players in the tumour microenvironment. Cancers (Basel) 2014;6:1670–1690.
67. Zhang J, Lu Y, Pienta KJ. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst 2010;102:522–528.
68. McLean K, Gong Y, Choi Y et al. Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumourigenesis via altered BMP production. J Clin Invest 2011;121:3206–3219.
69. Coffman LG, Choi YJ, McLean K et al. Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop. Oncotarget 2016;7:6916–6932.
70. Cuiffo BG, Campagne A, Bell GW et al. MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis. Cell Stem Cell 2014;15:762–774.
71. Li HJ, Reinhardt F, Herschman HR et al. Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov 2012;2:840–855.
72. Liu S, Ginestier C, Ou SJ et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011;71:614–624.
73. Wu XB, Liu Y, Wang GH et al. Mesenchymal stem cells promote colorectal cancer progression through AMPK/mTOR-mediated NF-κB activation. Sci Rep 2016;6:21420.
74. Tsai KS, Yang SH, Lei YP et al. Mesenchymal stem cells promote formation of colorectal tumors in mice. Gastroenterology 2011;141:1046–1056.
75. Lazennec G, Lam PY. Recent discovieries concerning the tumour-mesenchymnal stem cell interactions. Biochim Biophys Acta 2016;1866:290–299.
76. Pinilla S, Alt E, Abdul Khalek FJ et al. Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Lett 2009;284:80–85.
77. Klopp AH, Spaeth EL, Dembinski JL et al. Tumour irradiation increases the recruitment of circulating mesenchymal stem cells into the tumour microenvironment. Cancer Res 2007;67:11687–11695.
78. Haga H, Yan IK, Takahashi K et al. Tumour cell derived extracellular vesicles interact with mesenchymal stem cells to modulate the microenvironment and enhance cholangiocarcinoma growth. J Extracell Vesicles 2015;4:24900.
79. Lu YR, Yuan Y, Wang XJ et al. The growth inhibitory effect of mesenchymal stem cells on tumour cells in vitro and in vivo. Cancer Biol Ther 2008;7:245–251.
80. Ryu H, Oh JE, Rhee KJ et al. Adipose tissue-derived mesenchymal stem cells cultured at high density express IFN-β and suppress the growth of MCF-7 human breast cancer cells. Cancer Lett 2014;352:220–227.
81. Maccalli C, Parmiani G, Ferrone S et al. Immunomodulating and immunoresistance properties of cancer-initiating cells: Implications for the clinical success of immunotherapy. Immunol Invest 2017;46:221–238.
82. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–264.
83. Yoshimura A, Muto G. TGF-beta function in immune suppression. Curr Top Microbiol Immunol 2011;350:127–147.
84. Tallerico R, Todaro M, Di Franco S et al. Human NK cells selective targeting of colon cancer-initiating cells: A role for natural cytotoxicity receptors and MHC class I molecules. J Immunol 2013;190:2381–2390.
85. Ramasamy R, Tong CK, Seow HF et al. The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol 2008;251:131–136.
86. Di Ianni M, Del Papa B, De Ioanni M et al. Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 2008;36:309–318.
87. Kabashima-Niibe A, Higuchi H, Takaishi H et al. Mesenchymal stem cells regulate epithelial-mesenchymal transition and tumour progression of pancreatic cancer cells. Cancer Sci 2013;104:157–164.
88. McAndrews KM, McGrail DJ, Ravikumar N et al. Mesenchymal stem cells induce directional migration of invasive breast cancer cells through TGF-β. Sci Rep 2015;5:16941.
89. Maxwell PJ, Neisen J, Messenger J et al. Tumour-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells. Oncotarget 2014;5:4895–4908.
90. Li GC, Ye QH, Xue YH et al. Human mesenchymal stem cells inhibit metastasis of a hepatocellular carcinoma model using the MHCC97-H cell line. Cancer Sci 2010;101:2546–2553.
91. Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumour stem cells. Cancer Cell 2007;11:69–82.
92. Krishnamurthy S, Dong Z, Vodopyanov D et al. Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res 2010;70:9969–9978.
93. Mao Q, Zhang Y, Fu X et al. A tumour hypoxic niche protects human colon cancer stem cells from chemotherapy. J Cancer Res Clin Oncol 2013;139:211–222.
94. Orecchioni S, Gregato G, Martin-Padura I et al. Complementary populations of human adipose CD34+ progenitor cells promote growth, angiogenesis, and metastasis of breast cancer. Cancer Res 2013;73:5880–5891.
95. Otsu K, Das S, Houser SD et al. Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood 2009;113:4197–4205.
96. Vartanian A, Karshieva S, Dombrovsky V et al. Melanoma educates mesenchymal stromal cells towards vasculogenic mimicry. Oncol Lett 2016;11:4264–4268.
97. Tirino V, Desiderio V, Paino F et al. Cancer stem cells in solid tumours: An overview and new approaches for their isolation and characterization. FASEB J 2013;27:13–24.
98. Daverey A, Drain AP, Kidambi S. Physical intimacy of breast cancer cells with mesenchymal stem cells elicits trastuzumab resistance through Src activation. Sci Rep 2015;5:13744.
99. Teng IW, Hou PC, Lee KD et al. Targeted methylation of two tumour suppressor genes is sufficient to transform mesenchymal stem cells into cancer stem/initiating cells. Cancer Res 2011;71:4653–4663.
100. Shi Y, Du L, Lin L et al. Tumour-associated mesenchymal stem/stromal cells: Emerging therapeutic targets. Nat Rev Drug Discov 2017;16:35–52.
101. Tolar J, Nauta AJ, Osborn MJ et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007;25:371–379.
102. Kucerova L, Matuskova M, Hlubinova K et al. Tumour cell behaviour modulation by mesenchymal stromal cells. Mol Cancer 2010;9:129.
103. Gomes CM. The dual role of mesenchymal stem cells in tumour progression. Stem Cell Res Ther 2013;4:42.
104. Studeny M, Marini FC, Dembinski JL et al. Mesenchymal stem cells: Potential precursors for tumour stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004;96:1593–1603.
105. Zhang C, Yang SJ, Wen Q et al. Human-derived normal mesenchymal stem/stromal cells in anticancer therapies. J Cancer 2017;8:85–96.